Curetis celebrates dual listing on Euronext Amsterdam and Euronext Brussels
EnterNext, the Euronext subsidiary designed to promote and grow the market for SMEs, today celebrates the listing of Curetis. Trading in Curetis’ shares started this morning on Euronext Amsterdam and Euronext Brussels under the ticker code CURE.
Founded in 2007, Curetis is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases.
Oliver Schacht, CEO of Curetis said: “The IPO is a major milestone in Curetis´ corporate history and we are proud to join the group of renowned healthcare companies listed on Euronext. The proceeds of the transaction will mainly be used to expand the commercialization of our Unyvero Platform and to expand our product portfolio to address additional infectious diseases.”
For more information: www.curetis.com